Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock – Dyne Therapeutics (NASDAQ:DYN) – Stocks to Watch
  • Thu. May 16th, 2024
Top Tags
Commodities

Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock – Dyne Therapeutics (NASDAQ:DYN)

ByVandana Singh

Feb 27, 2023
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock - Dyne Therapeutics (NASDAQ:DYN)

[ad_1]

  • Raymond James has upgraded Dyne Therapeutics Inc DYN from Outperform to Strong Buy and raised the price target to $27 from $16.

  • The analyst notes proximity to myotonic dystrophy type 1 (DM1) data for DYNE-101 (2H23), for which it has high conviction, will be positive.

  • The ACHIEVE Phase 1/2 trial evaluating DYNE-101 for DM1 is underway. It includes a 24-week multiple ascending dose (MAD), a 24-week open-label extension, and a 96-week long-term extension. 

  • The ACHIEVE trial, designed to be registrational, is expected to enroll approximately 64 adult patients. Data from the MAD placebo-controlled portion of the ACHIEVE trial on safety, tolerability, and splicing are anticipated in the second half of 2023.

  • Raymond James also sees a substantial valuation gap with Avidity Biosciences Inc RNA, which should serve as a tailwind for DYN in 2023 between now and data (especially because the analyst thinks RNA will move higher also).

  • Related: Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew.

  • DYNE-101 will be a valuable therapeutic if initial low doses simply recapitulate the MARINA interim data profile without the SAE. 

  • Raymond James literature analysis drives conservative expectations on spliceopathy.

  • DM1 is, at its peak, a ~$9 billion revenue opportunity writes Raymond James analyst, which Dyne and Avidity will compete.

  • Price Action: DYN shares are up 10.3% at $12.79 on the last check Monday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.

Vandana Singh

Related Post

Commodities
Natural Gas Technical Analysis: Signs Point to Upside Momentum
Mar 31, 2023 FX Empire
Commodities
Here’s How Much $1000 Invested In Palo Alto Networks 5 Years Ago Would Be Worth Today – Palo Alto Networks (NASDAQ:PANW)
Mar 31, 2023 Benzinga Insights
Commodities
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,000 Today – NVIDIA (NASDAQ:NVDA)
Mar 31, 2023 Benzinga Insights

You missed


Notice: Function WP_Object_Cache::add was called incorrectly. Cache key must not be an empty string. Please see Debugging in WordPress for more information. (This message was added in version 6.1.0.) in /home/stockstowatch/public_html/wp-includes/functions.php on line 5835
Stocks
Stocks
Technology
Commodities